Brilacidin: Completed Phase IIb enrollment

Cellceutix completed enrollment of 215 patients with ABSSSI in a double-blind, U.S. Phase IIb trial comparing single IV doses of 0.6 and 0.8 mg/kg

Read the full 246 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE